NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

The unexplained write-off makes no sense; however, there is nothing at all 'fishy' about Advent's owner keeping all the retained earnings except for the small part that was invested in fixed assets. That goes without saying. It seems very clear also from the fact that NW still has to pay Advent's seller the outstanding AP from NW to Advent, and that NWBO isn't paying for any non-trivial amount of cash on Advent's books that would accrue to NWBO.

There's obviously something basic I don't understand about subsidiary finances vs the parent company, namely, why NW only had a relatively small AP to related parties on their books for 2024, while the AR on Advent's books and corresponding AP NW UK's was huge by comparison.